Johnson & Johnson 10-K Summary: Fiscal Year Ended January 2, 1994
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended January 2, 1994. Johnson & Johnson is a global healthcare company employing approximately 81,600 people. The company operates under a decentralized management structure with three primary business segments: Consumer (toiletries, baby care, first aid), Pharmaceutical (prescription drugs in allergy, CNS, and biotech fields), and Professional (surgical instruments, medical devices, and diagnostics). Operations span 43 countries outside the United States.
Key Financial Metrics
Note: The provided text incorporates the primary financial statements by reference to the Annual Report to Stockholders. Specific revenue, net income, and cash flow totals are not present in the text provided. The following metrics are derived from the included schedules:
- Research & Development Costs: $1,182 million for 1993 (compared to $1,127 million in 1992 and $980 million in 1991). These are expensed in the year incurred.
- Advertising Media Costs: $753 million for 1993 (compared to $694 million in 1992).
- Depreciation Expense: $553 million for 1993 (compared to $499 million in 1992).
- Short-Term Borrowings (Year-End): Total of $562 million, consisting of $126 million in Commercial Paper and $436 million in Notes Payable.
- Weighted Average Interest Rate: 7.1% on total short-term borrowings at year-end.
- Property, Plant, and Equipment (Net): The text provides gross additions of $975 million and retirements of $384 million for 1993, but does not state the final net book value.
- Market Capitalization: Approximately $23.6 billion (based on non-affiliate voting stock value as of March 1, 1994).
- Shares Outstanding: 643,161,600 shares as of March 1, 1994.
Material Changes and Operational Highlights
- Increased Investment in Growth: Research costs increased by approximately 5% year-over-year ($1,182M vs $1,127M), and advertising costs rose by roughly 8.5% ($753M vs $694M), indicating continued investment in product development and brand promotion.
- Capital Expenditures: Additions to property, plant, and equipment totaled $975 million in 1993, a decrease from $1,103 million in 1992.
- Debt Management: Total short-term borrowings decreased from $590 million in 1992 to $562 million in 1993. The weighted average interest rate on these borrowings dropped significantly from 8.5% in 1992 to 7.1% in 1993.
- Reserves: The reserve for customer rebates increased from $60 million to $87 million, reflecting higher allowances for rebates allowed ($379 million in 1993 vs $334 million in 1992).
Outlook, Risks, and Contingencies
Regulatory Environment: The company faces increasing regulatory stringency, particularly from the FDA regarding drug and device clearance, which increases time and expense for product introduction. Governmental focus on healthcare costs, drug pricing, and generic substitution (e.g., Medicaid rebates, Veterans Health Care Act) poses ongoing risks to revenue and margins.
Legal and Environmental: The company is involved in various administrative and judicial environmental proceedings (including Superfund). Management believes these will not have a material adverse effect on operations or financial position. No specific pending litigation details are provided in the text, as they are incorporated by reference.
Seasonality: Sales do not reflect significant seasonality, though spending is heavier in the fourth quarter due to advertising and research grants.
Guidance: The provided text does not contain specific forward-looking financial guidance or earnings projections for the upcoming fiscal year.
Investor Verification Checklist
- Verify total Net Sales and Net Earnings for 1993, 1992, and 1991 in the referenced Annual Report to Stockholders (pages 23-25 and 42).
- Review the Segment Reporting (pages 26-28 of the Annual Report) to analyze profitability by Consumer, Pharmaceutical, and Professional divisions.
- Examine Note 19 in the Annual Report for details on pending legal proceedings not summarized in this filing.
- Confirm the impact of currency translation adjustments on international operations, as noted in the Property and Depreciation schedules.
- Assess the long-term debt structure and maturity profile, as only short-term borrowings are detailed in the provided text.